Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Post-Marketing Real World Safety Study of Risankizumab in the United States

Psoriasis is a common, chronic, inflammatory disorder which primarily affects the skin and joints and is associated with impairment of quality of life. The main objective of this study is to assess how safe risankizumab is compared to other therapies in treating adult participants with psoriasis in real world setting in the United States. Adverse events will be assessed using secondary sources. Skyrizi (Risankizumab) is an approved drug for the treatment of moderate to severe psoriasis in the United States. Participants who are prescribed risankizumab or other comparator drugs in the real world setting will be included in this study. Data from approximately 3000 risankizumab new users and 12000 other comparator new users across the United States will be evaluated. Participants will receive subcutaneous risankizumab injection or other comparative drugs as prescribed by their physician. Data from these participants will be collected for approximately 10 years. There will be no additional burden for participants in this study compared to their standard of care as secondary data sources will be used.

Clinical Trial: Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Recruitment

Summary

Participation Requirements

Description

Tracking Information